HLN vs. LMAT: Which Stock Should Value Investors Buy Now?

Acadia Pharmaceuticals (ACAD) is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD's commercial portfolio comprises two marketed drugs — Nuplazid (pimavanserin) and Daybue (trofinetide). Revenues generated from the sales of Nuplazid are the majority contributor to Acadia's top line. In the first quarter of 2024, Nuplazid sales increased 10% year over year to $129.9 million, driven by improvem ...